J Korean Med Sci.  2012 Jul;27(7):830-833. 10.3346/jkms.2012.27.7.830.

Five-Year Review of HIV-Hepatitis B Virus (HBV) Co-Infected Patients in a New York City AIDS Center

• Kim JH
• Psevdos G
• Sharp V

• KMID: 2157934
• DOI: http://doi.org/10.3346/jkms.2012.27.7.830

Abstract

A retrospective review of 4,721 human immunodeficiency virus (HIV)-infected patients, followed at St. Luke's Roosevelt Hospital Center, New York City, was conducted from January 1, 2005 to December 31, 2009. HIV-Hepatitis B virus (HBV) co-infection rate was 218/4,721, 4.6%. Among co-infected patients, 19 patients (19/218, 8.7%) died; 13 patients (13/19, 68.4%) died from non-acquired immune deficiency syndrome (AIDS) defining including 2 patients with liver failure. More non-survivors (5 patients, 5/19, 26.3%) had liver cirrhosis than those who survived (8 patients, 8/199, 4.0%; P = 0.002). There were more patients with positive HBV e antigen (HBeAg) among non-survivors, (12 patients, 12/19, 63.2%) than among survivors (74 patients, 74/199, 37.2%; P = 0.047). HIV-HBV co-infection is associated with increased overall mortality. Therefore, use of dual active antiretrovirals, particularly, tenofovir (TDF) based regimen for optimal suppression of HIV-HBV and immune restoration with prevention of high risk behaviors may contribute to improved outcomes.

Keyword

HIV; Hepatitis B Virus; Mortality

MeSH Terms

Adenine/analogs & derivatives/therapeutic use
Adult
Anti-HIV Agents/therapeutic use
Coinfection/drug therapy/mortality
Female
HIV Infections/complications/*diagnosis/drug therapy
Hepatitis B/complications/*diagnosis/drug therapy
Hepatitis B e Antigens/blood
Humans
Liver Cirrhosis/etiology
Male
Middle Aged
New York City
Organophosphonates/therapeutic use
Retrospective Studies
Anti-HIV Agents
Hepatitis B e Antigens
Organophosphonates
Adenine

Reference

1. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006. 44:S6–S9.

2. Thio CL. Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment. Semin Liver Dis. 2003. 23:125–136.

3. Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Muñoz A, Thomas DL;. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002. 360:1921–1926.

4. Colin JF, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, Auperin A, Degott C, Benhamou JP, Erlinger S, Valla D, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology. 1999. 29:1306–1310.

5. Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic hepatitis B in co-infected patients. J Hepatol. 2006. 44:S65–S70.

6. Chu CJ, Keeffe EB, Han SH, Perrillo RP, Min AD, Soldevila-Pico C, Carey W, Brown RS Jr, Luketic VA, Terrault N, et al. Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology. 2003. 125:444–451.

7. Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: recent advances. J Gastroenterol Hepatol. 2011. 26:123–130.

8. Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD. HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006. 43:27–34.

9. Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis. 2010. 50:1387–1396.

10. Nikolopoulos GK, Paraskevis D, Hatzitheodorou E, Moschidis Z, Sypsa V, Zavitsanos X, Kalapothaki V, Hatzakis A. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin Infect Dis. 2009. 48:1763–1771.

11. Hoffmann CJ, Seaberg EC, Young S, Witt MD, D'Acunto K, Phair J, Thio CL. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients. AIDS. 2009. 23:1881–1889.

12. Boyd A, Lasnier E, Molina JM, Lascoux-Combe C, Bonnard P, Miailhes P, Wendum D, Meynard JL, Girard PM, Lacombe K. Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use. Antivir Ther. 2010. 15:963–974.

13. de Vries-Sluijs TE, Reijnders JG, Hansen BE, Zaaijer HL, Prins JM, Pas SD, Schutten M, Hoepelman AI, Richter C, Mulder JW, et al. Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. Gastroenterology. 2010. 139:1934–1941.

14. Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Chronic hepatitis B virus infection and mortality from non-liver causes: results from the Haimen City cohort study. Int J Epidemiol. 2005. 34:132–137.

15. Baumert TF, Thimme R, von Weizsäcker F. Pathogenesis of hepatitis B virus infection. World J Gastroenterol. 2007. 13:82–90.

16. Visvanathan K, Skinner NA, Thompson AJ, Riordan SM, Sozzi V, Edwards R, Rodgers S, Kurtovic J, Chang J, Lewin S, et al. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology. 2007. 45:102–110.

17. Jain MK. Mortality in patients coinfected with hepatitis B virus and HIV: could antiretroviral therapy make a difference? Clin Infect Dis. 2009. 48:1772–1774.

18. Tuma P, Jarrin I, Del Amo J, Vispo E, Medrano J, Martin-Carbonero L, Labarga P, Barreiro P, Soriano V. Survival of HIV-infected patients with compensated liver cirrhosis. AIDS. 2010. 24:745–753.